Tata Nifty MidSmall Healthcare Index Fund

A Index Funds scheme from Tata Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF277KA1BG3).

NAV ₹15.7477 on 16 November 2026.

Expense ratio

Total expense ratio 0.58% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.37%, brokerage 0.02%, transaction costs 0.00%, statutory levies including GST 0.19%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year21.5%15.8%-10.4%0.921.00

Too little NAV history for the 3, 5, 10-year figures.

Not ranked in its category: its category mixes funds too different to rank against one another.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 100.2% of the portfolio.

  1. Laurus Labs Limited — 14.12%
  2. Lupin Limited — 7.36%
  3. Aurobindo Pharma Limited — 7.00%
  4. Fortis Healthcare Limited — 6.03%
  5. Glenmark Pharmaceuticals Limited — 5.22%
  6. Alkem Laboratories Limited — 4.65%
  7. Mankind Pharma Limited — 4.26%
  8. IPCA Laboratories Limited — 4.04%
  9. Gland Pharma Limited — 3.72%
  10. Biocon Limited — 3.70%

Plans

Other funds in Index Funds

All 275 funds in Index Funds · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.